David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

A sign for Eli Lilly & Co ... Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its ...

Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...

Eli Lilly and Company discovers ... and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before ...